Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s134398
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2017
Authors
Publisher
Informa UK Limited